Drugs / almotriptan
almotriptan
also known as
almotriptan malate · AXERT · Almogran · Almotriptan d,l-hydrogenmalate · Almotriptan maleate · LAS 31416 · LAS 31416 D,L-MALATE ACID · NSC-760092 · +1 more
Small molecule targets HTR1B, HTR1D, HTR1F via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | AXERT | — | 2009-04-30 | fda.gov ↗ |
| Approved | US (FDA) | AXERT | — | 2001-05-07 | fda.gov ↗ |
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT00257010 | Dec 2005 → Dec 2007 | migraine disorder | Janssen-Ortho LLC | Completed | No outcome recorded |
| Phase 3 | NCT00210483 | Jul 2003 → Jul 2005 | migraine disorder | Janssen-Ortho LLC | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT05214001 | Jun 2022 → Apr 2024 | migraine with aura, migraine without aura | Messoud Ashina, MD | Terminated | No outcome recorded |
| Phase 4 | NCT00432549 | Jan → Feb 2007 | — | The New England Center for Headache, P.C. | Unknown | No outcome recorded |
| Phase 4 | NCT00210496 | Jun 2005 → Jun 2007 | migraine with aura, migraine without aura | Janssen-Ortho LLC | Completed | No outcome recorded |
| Phase 4 | NCT00210509 | Nov 2004 → Jun 2005 | migraine disorder | Janssen-Ortho LLC | Completed | No outcome recorded |
| Phase 4 | NCT00212823 | Jun 2004 → Feb 2005 | migraine disorder | Ortho-McNeil Neurologics, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00208065 | May 2004 → Nov 2005 | migraine disorder, sinusitis | Clinvest | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01086358 Comparator | Sep 2009 → Aug 2016 | — | The Cleveland Clinic | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-07-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva First to Receive Approval and Launch Generic Axert® Tablets in the United States tevapharm.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | almotriptan | “Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan” NCT01086358 ↗ |
| Known as | Almogran | ChEMBL registry synonym — accepted as the source's own label CHEMBL1505 ↗ |
| Known as | Almotriptan d,l-hydrogenmalate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1505 ↗ |
| Known as | almotriptan malate | “A Randomized, Double-blind, Placebo-controlled Study of Oral Almotriptan Malate (AXERT®) 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents” NCT00210483 ↗3“The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain” NCT00212823 ↗ |
| Known as | Almotriptan maleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1505 ↗ |
| Known as | AXERT | “A Randomized, Double-blind, Placebo-controlled Study of Oral Almotriptan Malate (AXERT®) 6.25 mg, 12.5 mg, and 25 mg in the Acute Treatment of Migraine in Adolescents” NCT00210483 ↗3“Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate)” NCT00210496 ↗ “Almotriptan malate (AXERT®) 12.5 milligram tablets compared with placebo for the acute treatment of migraine headache” NCT00210509 ↗ “The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain” NCT00212823 ↗ |
| Known as | LAS 31416 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1505 ↗ |
| Known as | LAS 31416 D,L-MALATE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL1505 ↗ |
| Known as | NSC-760092 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1505 ↗ |
| Known as | PNU-180638E | ChEMBL registry synonym — accepted as the source's own label CHEMBL1505 ↗ |
| Action | Activate | “Serotonin 1d (5-HT1d) receptor agonist” CHEMBL1505 ↗2“Serotonin 1b (5-HT1b) receptor agonist” CHEMBL1505 ↗ “Serotonin 1f (5-HT1f) receptor agonist” CHEMBL1505 ↗ |
| Modality | Small molecule | — CHEMBL1505 ↗ |
| Route | Oral | “receive one oral dose of almotriptan malate (AXERT®) 6.25, 12.5, or 25 milligrams or placebo” NCT00210483 ↗ |
| Target | HTR1B | “Serotonin 1b (5-HT1b) receptor agonist” CHEMBL1505 ↗ |
| Target | HTR1D | “Serotonin 1d (5-HT1d) receptor agonist” CHEMBL1505 ↗ |
| Target | HTR1F | “Serotonin 1f (5-HT1f) receptor agonist” CHEMBL1505 ↗ |